[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"myeloma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:myeloma":36},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,28,0,25,[9,56,79,114,147,175,198,227,248,280,304,327,348,374,394,436,470,487,503,519,543,564,589,611,635],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":45,"lastUpdatePostDateStruct":46,"startDateStruct":49,"completionDateStruct":50,"leadSponsor":52,"locationsCount":55},"100590778","evaluation-of-skin-tests-in-biotherapy-allergies-100590778",false,"NCT06971848","Evaluation of Skin Tests in Biotherapy Allergies","ETCABIO","Inclusion Criteria :\n\n* Patient treated with one of the biotherapies under study (Atezolizumab 1200 mg, Nivolumab 480 mg, Obinutuzumab 100 mg, Durvalumab 1500 mg, Pembrolizumab 200 mg, Daratumumab 1800 mg, Cemiplimab 3500 mg) and who has received at least two injections of the biotherapy without suspected allergic side effects.\n* Subjects covered by or having the rights to medical care assurance\n* Written informed consent obtained from subject\n* If applicable, treatment with corticosteroids and H1 antihistamines by systemic route (IV or oral) which may be discontinued at least one week before performing the tests (Inhaled corticosteroids are allowed).\n\nExclusion Criteria:\n\n* Presence of local or diffuse dermatological lesions (e.g., psoriasis, eczema, ...) that could interfere with the interpretation of skin tests.\n* Poor understanding of the French language\n* Pregnancy, breastfeeding\n* Persons in detention by judicial or administrative decision\n* Person admitted to a health or social establishment for purposes other than research\n* Person subject to a legal protection measure",true,"ALL","18 Years",{"count":21,"type":22},70,"ESTIMATED","INTERVENTIONAL",[25],"NA","Biotherapies are biological (extracted from an organism or living tissue) or biotechnological drugs used in the treatment of multiple conditions, such as autoimmune inflammatory diseases, cancers, and hematologic diseases. In recent years, these biotherapies have notably emerged in the treatment of cancers and hematologic disorders. As such, most patients with cancers or hematologic diseases will likely receive a biotherapy as part of their care pathway.\n\nThese biotherapies are associated with various side effects, including hypersensitivity or allergic reactions, which are often poorly characterized in clinical trials. These reactions manifest as symptoms without specific dermatologic or allergologic semiology (such as itching, erythema, shortness of breath, sometimes digestive issues, or discomfort, and in some cases, an anaphylactic reaction).\n\nUnlike other treatments, such as antibiotics and neuromuscular blockers, there are currently no guidelines on the concentrations to use in skin tests for biotherapies. We propose conducting prospective clinical research to scientifically establish the concentrations to be used when investigating hypersensitivity to a biotherapy, in line with best practice recommendations for drug skin testing.",[28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43],"Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck","Melanoma Neoplasms","Small Cell Bronchial Carcinomas","Bronchial Carcinoma","Pleural Mesothelioma","Hodgkin's Lymphoma","Chronic Lymphocytic Leukemia","Follicular Lymphoma","Myeloma","AL Amyloidosis","Hepatocarcinoma","Colorectal Cancer","Esophageal Squamous Cell Carcinoma","Heart Cancer","Cholangiocarcinoma","Colorectal Adenocarcinoma","RECRUITING","2026-06-17",{"date":47,"type":48},"2026-06-18","ACTUAL",{"date":45,"type":48},{"date":51,"type":22},"2028-07",{"name":53,"class":54},"University Hospital, Angers","OTHER_GOV",1,{"id":57,"slug":58,"hasResults":12,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":4,"eligibilityCriteria":62,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":63,"targetDuration":4,"studyType":23,"phases":65,"briefSummary":67,"conditions":68,"keywords":4,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":55},"100443489","phase-1-a-phase-1-with-extension-cohort-single-arm-single-center-open-label-trial-of-belantamab-mafodotin-for-the-treatment-of-high-risk-smoldering-multiple-myeloma-100443489","NCT05055063","A Phase 1 With Extension Cohort, Single Arm, Single Center, Open Label Trial of Belantamab Mafodotin for the Treatment of High-Risk Smoldering Multiple Myeloma","A Phase 1 With Extension Cohort, Single Arm, Single Center, Open Label Trial of Belantamab Mafodotin for the Treatment of High-Risk Smoldering Multiple Myeloma (BELLA)","Inclusion Criteria:\n\nPatients must be diagnosed with high-risk smoldering multiple myeloma (SMM) as confirmed by the following (all three must be present):\n\n1. Bone marrow plasmacytosis with ≥ 10% plasma cells in bone marrow biopsy\n2. Immunoparesis (reduction in at least one uninvolved immunoglobulin in blood)\n3. ≥ 95% aberrant plasma cells of all plasma cells by flow cytometry of the bone marrow aspirate\n\n   * Creatinine clearance (CrCl) ≥ 30 ml\u002Fmin. CrCl will be calculated using the Modification of Diet in Renal Disease (MDRD) equation.\n   * Age ≥ 18 years.\n   * Eastern Cooperative Oncology Group (ECOG) performance status 0-2\n   * Absolute neutrophil count (ANC) ≥ 1.0 x 109 \u002FL, hemoglobin more or equal than 2 grams below the institutional level of normal and platelet count ≥ 90 x 109\u002FL. Platelet and blood transfusions are allowed on protocol. Growth factors, including granulocyte colony stimulating factors and erythropoietin are allowed.\n   * Adequate hepatic function, with bilirubin ≤ 1.5 x the ULN, and AST and ALT ≤ 2.5 x ULN.\n   * Females of childbearing potential are eligible to participate if they agree to avoid pregnancy by using an adequate method of contraception that is highly effective with a failure rate of \\\u003C1% per year (2 barrier method or 1 barrier method with a spermicide or intrauterine device during and for 4 months after the last dose of belantamab mafodotin). Adequate methods of contraception are provided as examples. Other acceptable and effective methods of birth control are also permitted (eg, abstinence). Women of child bearing potential must have a negative serum pregnancy test result within 72 hours prior to the first administration of belantamab mafodotin and at the end of treatment visit. A negative urine pregnancy test is required prior to each subsequent belantamab mafodotin dose administration\n   * Females of childbearing potential are eligible to participate if they agree to notdonate eggs (ova, oocytes) for the purpose of reproduction during the study and for 4 months after the last dose of belantamab mafodotin.\n   * Male participants are eligible to participate if they agree to the following from the time of first dose of belantamab mafodotin until 6 months after the last dose of study treatment to allow for clearance of any altered sperm:\n\n     * be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) and agree to remain abstinent,\n     * OR must agree to use contraception\u002Fbarrier as follows:\n     * agree to use a male condom, even if they have undergone a successful vasectomy\n     * and female partner of childbearing potential to use an additional highly effective contraceptive method with a failure rate of \\\u003C1% per year when having sexual intercourse.\n   * Men must agree to not donate sperm while on the study and for at least 6 months after the last dose of belantamab mafodotin.\n   * Subjects must be able to give informed consent.\n   * Subjects must be either newly diagnosed smoldering myeloma or not have received prior or concurrent treatment for smoldering multiple myeloma with chemotherapy agents approved for the treatment of smoldering multiple myeloma. Patients who have been treated previously on a clinical trial or with non-approved agents for their smoldering myeloma can be included.\n   * Exclusion Criteria:\n   * Evidence of myeloma defining events or biomarkers of malignancy due to underlying plasma cell proliferative disorder meeting at least one of the following:\n\n     * Hypercalcemia: serum calcium \\>0.25 mmol\u002FL (\\>1 mg\u002FdL) higher than the upper limit of normal or \\> 2.75 mmol\u002FL (\\> 11 mg\u002FdL)\n     * Renal Insufficiency: creatinine clearance \\\u003C 40 ml\u002Fmin or serum creatinine \\> 2 mg\u002FdL\n     * Anemia: hemoglobin value more than 2 g\u002FdL \\\u003C normal reference\n     * Bone lesions: one or more osteolytic lesions on skeletal radiography, computerized tomography (CT) or 2-deoxy-2\\[F-18\\] fluoro-D-glucose positron emission tomography CT (PET-CT).\n     * Clonal bone marrow plasma cell percentage ≥ 60%\n     * Involved: uninvolved serum free light chain ratio ≥100 measured by Freelite assay (The Binding Site Group, Birmingham, UK)\n     * \\>1 focal lesions on MRI studies (each focal lesion must be 5 mm or more in size)\n   * Bisphosphonates are permitted, including pamidronate, zoledronic acid, alendronate, ibandronate, risedronate.\n   * Treatment with corticosteroids is not permitted, unless the patient is on a stable chronic dose of inhaled steroids to treat respiratory diseases or on stable chronic steroid replacement therapy for endocrinology disorders. Steroids may be used treat infusion related reactions. Inhaled, intranasal, and topical ophthalmic steroids are not prohibited.\n   * Radiotherapy is not permitted.\n   * Prior or concurrent treatment for smoldering multiple myeloma with chemotherapy agents approved for the treatment of smoldering multiple myeloma\n   * Plasma cell leukemia\n   * Pregnant or lactating females. It is not known whether belantamab mafodotin is excreted in human milk. The effect of belantamab mafodotin of newborns\u002Finfants is unknown. Women should be advised to discontinue breast-feeding prior to initiating treatment with belantamab mafodotin and for at least 70 days after the last dose. These potential risks may also apply to other agents used in this study.\n   * Active hepatitis B or C infection\n   * Known HIV infection\n   * Known immediate or delayed hypersensitivity reaction or idiosyncratic reaction to drugs chemically related to belantamab mafodotin\n   * Concurrent treatment with other anti-cancer therapy is not permitted\n   * Has significant cardiovascular disease with:\n\n     * NYHA Class III or IV symptoms,\n     * uncontrolled hypertension\n     * hypertrophic cardiomyopathy restrictive cardiomyopathy, or myocardial infarction, acute coronary syndromes (including unstable angina), coronary angioplasty, or stenting or bypass grafting within 3 months prior to enrollment\n     * evidence of current clinically significant uncontrolled arrhythmias, including clinically significant ECG abnormalities such as 2nd degree (Mobitz Type II) or 3rd degree atrioventricular (AV) block as determined by history and physical examination.\n   * Uncontrolled intercurrent illness including but not limited to active infection requiring treatment or psychiatric illness\u002Fsocial situations that would compromise compliance with study requirements\n   * Contraindication to any concomitant medication, including pre-medications or hydration given prior to therapy\n   * Major surgery within 1 month prior to enrollment\n   * Previous or concurrent malignancies other than disease under study, unless the second malignancy has been medically stable for at least 2 years and, in the opinion of the principal investigators, will not affect the evaluation of the effects of clinical trial treatments on the currently targeted malignancy. Participants with curatively treated non-melanoma skin cancer may be enrolled without a 2-year restriction.\n   * Presence of active renal condition (infection, requirement for dialysis, or any other condition that could affect participant's safety). Participants with isolated proteinuria resulting are eligible, provided they fulfil renal criteria provided above.\n   * Any evidence of active mucosal or internal bleeding\n   * Received prior treatment with a monoclonal antibody within 30 days of receiving the first dose of belantamab mafodotin\n   * Cirrhosis or current unstable liver or biliary disease defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices, persistent jaundice, or cirrhosis. Note: Stable non-cirrhotic chronic liver disease (including Gilbert's syndrome or asymptomatic gallstones) or hepatobiliary involvement of malignancy is acceptable if otherwise meets entry criteria\n   * Current corneal epithelial disease except mild changes in corneal epithelium\n   * Use of contact lenses while participating in this study, except at the direction of the study MD\u002FOD\n   * Severe dry eye patients and monocular patients are excluded",{"count":64,"type":22},30,[66],"PHASE1","This is a single-center, single arm, phase I study designed to determine the safety and find the recommended Phase 2 dose (RP2D) or maximum dose level (MTD) of Belantamab Mafodotin in patients with high-risk smoldering multiple myeloma. The study will have a dose-finding part and a dose-expansion part. The maximum number of enrolled patients will be 30 with 18 patients for the dose-finding part and 12 patients for the dose-expansion part. Once we determine the MTD or RP2D in the dose-finding part, we will enroll and treat 12 additional patients at the MTD or RP2D in the expansion part. Efficacy will be assessed through the overall response rate (ORR) at the end of the study. With the limited number of patients for the dose-expansion part, we will not have formal futility monitoring rule.",[36],"2026-06-09",{"date":71,"type":48},"2026-06-11",{"date":73,"type":48},"2022-05-18",{"date":75,"type":22},"2027-02-02",{"name":77,"class":78},"M.D. Anderson Cancer Center","OTHER",{"id":80,"slug":81,"hasResults":12,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":85,"eligibilityCriteria":86,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":87,"targetDuration":4,"studyType":23,"phases":89,"briefSummary":91,"conditions":92,"keywords":98,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":113},"100434327","phase-2-faecal-microbiota-transplantation-after-allogeneic-stem-cell-transplantation-100434327","NCT04935684","Faecal Microbiota Transplantation After Allogeneic Stem Cell Transplantation","Faecal Microbiota Transplantation for Prevention of Graft-versus-host Sisease After Allogeneic Stem Cell Transplantation for Haematological Malignancies","TMF-Allo","Inclusion Criteria:\n\n* Patient aged 18 or over\n* Men and women\n* Patients affiliated with a social-security organization\n* Patients undergoing a myelo-ablative allo-HSCT for a controlled haematologic malignant disease, with peripheral stem cells, whatever the type of donor (except cord blood)\n* Signed and dated informed consent\n\nExclusion Criteria:\n\n* Status of tumor progression at the time of allo-HSCT\n* Inability to understand the protocol (linguistic barrier, cognitive difficulties)\n* Medical history of another progressive cancer or occurrence in the 3 previous years (excluding basal cell carcinoma)\n* Presence of a simultaneous serious and uncontrolled disease (severe cardiac, renal, hepatic or respiratory failure, severe sepsis)\n* Fecal incontinence\n* Participation in another clinical trial studying an allograft procedure including the type of graft, the type of immunosuppression, a preventive or a curative treatment of GvHD, or studying the effectiveness of a FMT in another indication.\n* Pregnant women\n* Patient under guardianship, curatorship or protection of justice",{"count":88,"type":22},150,[90],"PHASE2","The aim of this study is to assess the Fecal Microbiota Transplantation (FMT) efficacy in the prevention of allogeneic hematopoietic stem cell transplantation (allo-HSCT) complications and particularly Graft versus Host Disease (GvHD).\n\nThe hypothesis of this study is that allogeneic FMT may improve outcomes of these patients.",[93,94,95,96,97,36,34],"Acute Leukemia in Remission","Myelodysplastic Syndromes","Myeloproliferative Syndrome","Hodgkin Lymphoma","Lymphoma, Non-Hodgkin",[99,100,101,102,103,104],"Allogeneic hematopoietic stem cell transplantation","Hematologic malignancies","Graft versus Host Disease","Intestinal microbiota","Intestinal dysbiosis","Fecal Microbiota Transplantation","2026-06-08",{"date":69,"type":48},{"date":108,"type":48},"2022-12-20",{"date":110,"type":22},"2030-05",{"name":112,"class":78},"University Hospital, Clermont-Ferrand",20,{"id":115,"slug":116,"hasResults":12,"nctId":117,"briefTitle":118,"officialTitle":119,"acronym":4,"eligibilityCriteria":120,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":121,"targetDuration":4,"studyType":23,"phases":123,"briefSummary":124,"conditions":125,"keywords":128,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":137,"lastUpdatePostDateStruct":138,"startDateStruct":139,"completionDateStruct":141,"leadSponsor":143,"locationsCount":146},"100489347","phase-1-a-study-of-an-mmset-inhibitor-in-patients-with-relapsed-and-refractory-multiple-myeloma-100489347","NCT05651932","A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma","A Phase 1 Study of KTX-1001, an Oral, First-In-Class, Selective, and Potent MMSET Catalytic Inhibitor That Suppresses H3K36me2 in Patients With Relapsed and Refractory Multiple Myeloma","Key Inclusion Criteria for Dose-Expansion:\n\n* ≥ 18 years of age\n* ECOG score ≤ 1\n* Multiple myeloma (as per IMWG)\n\n  * Prior therapy for MM: Participants must have received at least 1 and up to 3 prior lines of therapy as defined by IMWG, and the following drug classes: PI, IMiD, and anti-CD38 antibody. For mezigdomide combination Cohorts B1 and B2, participants must have received at least 2 prior lines of therapy\n  * Participants must have a confirmed diagnosis of progressive MM (per IMWG), t(4;14) confirmed by fluorescence in situ hybridization (FISH) testing performed in a centralized Clinical Laboratory Improvement Amendments (CLIA) accredited laboratory via fresh tumor biopsy.\n* Measurable disease, including at least 1 of the following criteria:\n\n  * Serum M protein ≥ 0.50 g\u002FdL (by SPEP)\n  * Serum IgA ≥ 0.50 g\u002FdL (IgA myeloma patients)\n  * Urine M protein ≥ 200 mg\u002F24 h (by UPEP)\n  * sFLC involved light chain ≥ 10 mg\u002FdL (100 mg\u002FL) (patients with abnormal sFLC ratio)\n  * Bone marrow plasma cells ≥ 30% (if only criterion for measurability)\n* Agreement to enroll into the REMS program (Cohort D- pomalidomide cohort only)\n\nKey Exclusion Criteria for Dose-Expansion:\n\n* Treatment with the following therapies in the specified time period prior to first dose:\n\n  * Patients in Cohorts B1 and B2 must not have received prior mezigdomide treatment\n  * Carfilzomib in the immediate last prior line of therapy for patients enrolled in Cohorts C1 and C2\n  * Pomalidomide in the immediate last prior line of therapy for patients enrolled in cohort D\n  * Radiation, chemotherapy, immunotherapy, or any other anticancer therapy ≤ 2 weeks\n  * Cellular therapies ≤ 8 weeks\n  * Autologous transplant \\\u003C 100 days\n  * Allogenic transplant ≤ 6 months, or \\> 6 months with active GVHD\n  * Major surgery ≤ 4 weeks\n* Current plasma cell leukemia, POEMS (polyneuropathy, organomegaly, endocrinopathy, and skin changes) syndrome, solitary bone lesion or bone lesions as the only evidence for plasma cell dyscrasia, myelodysplastic syndrome or a myeloproliferative neoplasm or light chain amyloidosis\n* Active CNS disease: participants with previously treated stable CNS disease are eligible, except for Cohorts B1 and B2 for which known CNS myeloma involvement is completely excluded.\n* Inadequate bone marrow function\n* Inadequate renal, hepatic, pulmonary, and cardiac function\n* Active, ongoing, or uncontrolled systemic viral, bacterial, or fungal infection. Permitted prophylactic medications, antimicrobials or antiretroviral therapies defined in protocol.\n* Use of acid reducing agents and strong inhibitors or inducers of CYP3A4 within 7 days or 5 half-lives (whichever is longer) prior to first dose\n* Strong CYP1A2 inhibitors for patients receiving pomalidomide (Cohort D)\n* Active malignancy not related to myeloma requiring therapy within \\\u003C 2 years prior to enrollment, or not in complete remission, with exceptions defined in protocol.",{"count":122,"type":22},165,[66],"A Phase I study to evaluate the safety of a novel, orally available, selective, and potent small molecule inhibitor of the histone lysine methyl transferase MMSET (also known as NSD2\u002FWHSC1) to prevent the dimethylation of H3K36 in adult patients with relapsed or refractory multiple myeloma (RRMM).",[126,36,127],"Multiple Myeloma","Myeloma Multiple",[129,130,131,132,133,134,135,136],"NSD2","MMSET","WHSC1","T4;14","T(4;14)","translocation","myeloma","RRMM","2026-06-04",{"date":105,"type":48},{"date":140,"type":48},"2023-02-22",{"date":142,"type":22},"2028-06-30",{"name":144,"class":145},"K36 Therapeutics, Inc.","INDUSTRY",22,{"id":148,"slug":149,"hasResults":12,"nctId":150,"briefTitle":151,"officialTitle":152,"acronym":4,"eligibilityCriteria":153,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":154,"targetDuration":4,"studyType":23,"phases":156,"briefSummary":157,"conditions":158,"keywords":162,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":166,"lastUpdatePostDateStruct":167,"startDateStruct":169,"completionDateStruct":171,"leadSponsor":173,"locationsCount":174},"100597010","a-music-therapy-study-for-blood-cancer-survivors-with-cognitive-difficulties-100597010","NCT07052916","A Music Therapy Study for Blood Cancer Survivors With Cognitive Difficulties","Pilot Trial of Telehealth Music Therapy for Cognitive Dysfunction in Hematologic Cancer Survivors (PRELUDE)","Inclusion Criteria:\n\n* English-proficient, aged 18 or older\n* Diagnosis of lymphoma, leukemia, or myeloma\n* Stable oncologic disease or no evidence of disease as indicated in the medical chart or by the oncology team\n* Score of \\\u003C54 on the FACT-Cog PCI subscale\n* Minimum life expectancy of one year as per clinician assessment\n* Patient should be able to understand and complete all study assessments on their own.\n* Eligible patient should be able to understand informed consent and provide signed informed consent in English.\n\nExclusion Criteria:\n\n* Less than 3 months since completion of surgery, radiation, induction chemotherapy (for newly diagnosed or relapsed disease), transplantation, or immunotherapy (e.g., CAR T-Cell, bispecific antibodies)\n\n  * If there is a defined treatment period, the patient must be at least 3 months from treatment completion\n  * If the patient is on continuous therapy, patient must have completed at least 6 months of the therapy\n  * Maintenance therapies are allowed\n* Received music therapy (MT) in the past year\n* Current music training, \\>6 months of music training in the past 10 years, or plan to initiate music training during the study\n* No access to an internet-connected device\n* Active suicidal ideation, bipolar, schizophrenia, or substance abuse\n* BOMC score ≥10 (indicative of dementia)\n* Uncorrectable visual, auditory, or motor impairments\n* Initiation or altered dose of sedative, stimulant, or anti-cholinergic medications in the past month or plan to initiate these medications during the study, as these are known to impact cognitive function\n* Initiation of any other interventions for CRCD (e.g., cognitive rehabilitation) in the past month or plan to initiate these interventions during the study, as these are known to impact cognitive function",{"count":155,"type":22},60,[25],"Research has shown that music-based activities may help improve brain functions, such as attention, memory, and executive function. Because of this past research, the researchers are doing this study to find out whether telehealth music therapy is a practical treatment for cognitive difficulties in blood cancer survivors. The researchers will also study whether music therapy and music education help improve cognitive function and other common symptoms such as anxiety, depression, and\u002For tiredness.",[159,160,161,36],"Blood Cancer","Lymphoma","Leukemia",[163,135,161,160,164,165],"Blood cancer survivor","Memorial Sloan Kettering Cancer Center","25-119","2026-05-22",{"date":168,"type":48},"2026-05-26",{"date":170,"type":48},"2025-06-27",{"date":172,"type":22},"2026-12-27",{"name":164,"class":78},7,{"id":176,"slug":177,"hasResults":12,"nctId":178,"briefTitle":179,"officialTitle":180,"acronym":181,"eligibilityCriteria":182,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":183,"targetDuration":4,"studyType":23,"phases":185,"briefSummary":186,"conditions":187,"keywords":4,"overallStatus":188,"whyStopped":4,"lastUpdateSubmitDate":189,"lastUpdatePostDateStruct":190,"startDateStruct":192,"completionDateStruct":194,"leadSponsor":196,"locationsCount":55},"100639133","phase-1-etenta-isa-vrd-in-newly-diagnosed-high-risk-multiple-myeloma-100639133","NCT07600151","Etenta-Isa-VRd in Newly Diagnosed High-Risk Multiple Myeloma","A Clinical Phase I\u002FII, Multicenter, Open-label, National Study Evaluating Quintuplet Treat-ment With ISaTuximab, Bortezomib, Lenalidomide and Dexamethasone Plus Etentamig (Etenta-Isa-VRd) in Primary DiagnOsed High-Risk Multiple Myeloma Patients","CONQUISTADOR","Inclusion Criteria:\n\n* Participants must have confirmed diagnosis of symptomatic MM per IMWG criteria.\n* Participants must have High-risk myeloma according to IMS\u002FIMWG CGS\n* Participants must be considered a candidate for high-dose chemotherapy and ASCT, as described in the protocol.\n* Participants must have measurable disease as defined in the protocol. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 (WHO=3 is allowed only if caused by MM and not by co-morbid conditions).\n* Participants must have clinical laboratory values within a prespecified range.\n\nExclusion Criteria:\n\n* Known contraindications to the use of any IMP or axMP or required concomitant drugs or supportive treatment.\n* known systemic amyloidosis (except for AL amyloidosis of the skin or the bone marrow), POEMS syndrome, Waldenstrom's macroglobulinemia; primary plasma cell leukemia\n* Administration of systemic therapy for multiple myeloma except osteoprotective therapy. Emergency myeloma treatment with dexamethasone is allowed according to specifications in the protocol. It is allowed to include patients after 1 cycle of any anti-myeloma first-line treatment within the specifications of the protocol\n* known central nervous system involvement by MM.",{"count":184,"type":22},220,[66,90],"This study is researching an experimental five-drug combination called etentamig, isatuximab, bortezomib, lenalidomide, and dexamethasone. The study is focused on participants with newly diagnosed multiple myeloma (NDMM) and high-risk disease who are eligible for autologous stem cell transplantation.",[127,36],"NOT_YET_RECRUITING","2026-05-14",{"date":191,"type":48},"2026-05-20",{"date":193,"type":22},"2026-12-01",{"date":195,"type":22},"2036-12-31",{"name":197,"class":78},"Universitätsklinikum Hamburg-Eppendorf",{"id":199,"slug":200,"hasResults":12,"nctId":201,"briefTitle":202,"officialTitle":203,"acronym":204,"eligibilityCriteria":205,"healthyVolunteers":12,"sex":18,"minAge":206,"maxAge":207,"enrollmentInfo":208,"targetDuration":4,"studyType":23,"phases":209,"briefSummary":210,"conditions":211,"keywords":215,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":217,"lastUpdatePostDateStruct":218,"startDateStruct":220,"completionDateStruct":222,"leadSponsor":224,"locationsCount":226},"100334406","phase-1-pilot-imaging-study-of-leukemia-100334406","NCT03633955","Pilot Imaging Study of Leukemia","Multi-institutional Prospective Pilot Study of Radiology Evaluation of Acute Leukemia Infiltration analyZed by Experimental Imaging","REALIZE","Inclusion Criteria:\n\n1. Aged 4 to 80 years\n2. Evidence of high-risk hematopoietic malignancy with relapsed\u002Frefractory disease: acute lymphocytic leukemia, Acute myeloid leukemia, Ambiguous lineage leukemia, myeloma\n3. Karnofsky\u002FLansky score of ≥ 50\n4. Agree to use contraceptive measures during study protocol participation (when age appropriate)\n5. Patient or parent\u002Fguardian capable of providing informed consent.\n6. Ability to undergo 18F FLT imaging without sedation\n7. Bilirubin \\\u003C 2.5 mg\u002FdL, AST\u002FALT \\\u003C5x upper limit of normal, Serum creatinine \\\u003C 1.0 or 2x the upper limit of normal (whichever is higher)\n8. Pulse oximetry of \\> 90% on room air\n9. Ability to undergo 18F FLT imaging without sedation\n10. Anticipated immunotherapy (Arm A to include patients who received immune therapy with co-enrollment on a separate protocol or other immunotherapy) and Arm B, those who received other non-immune therapies to treat their cancers (excludes HSCT but includes chemotherapy or non-HSCT radiotherapy).\n\nExclusion Criteria:\n\n1. Patients with uncontrolled infections\n2. Pregnancy or lactating\n3. History of prior fluorothymidine allergy or intolerance.","4 Years","80 Years",{"count":155,"type":22},[66],"This is a prospective pilot study, the primary aim of which is to determine whether the presence of 18F FLT imaging signal uptake abnormalities correlate with clinically validated evidence of hematopoietic malignant disease (e.g. MRD, molecular, flow or histology) after immunotherapy and other treatments.",[212,213,214,36],"Acute Lymphocytic Leukemia","Acute Myeloid Leukemia","Ambiguous Lineage Leukemia or Lymphoma",[216],"FLT","2026-04-21",{"date":219,"type":48},"2026-04-23",{"date":221,"type":48},"2023-01-19",{"date":223,"type":22},"2029-04",{"name":225,"class":78},"University of Oklahoma",3,{"id":228,"slug":229,"hasResults":12,"nctId":230,"briefTitle":231,"officialTitle":232,"acronym":233,"eligibilityCriteria":234,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":235,"targetDuration":4,"studyType":237,"phases":4,"briefSummary":238,"conditions":239,"keywords":4,"overallStatus":188,"whyStopped":4,"lastUpdateSubmitDate":240,"lastUpdatePostDateStruct":241,"startDateStruct":243,"completionDateStruct":245,"leadSponsor":246,"locationsCount":55},"100633883","real-world-maia-uk-outcomes-100633883","NCT07532473","REal World MAIA UK OutcomEs","A Retrospective Study of Clinical Outcomes in Newly Diagnosed, Transplant Ineligible Multiple Myeloma Patients Treated With Daratumumab, Lenalidomide and Dexamethasone (DRd) Outside of Clinical Trials in the UK","REMAKE","Inclusion Criteria:\n\n* Age ≥18 years\n* Diagnosis of NDMM\n* Not eligible for autologous stem cell transplant at diagnosis\n* Received frontline DRd treatment following NICE approval (post-September 2023)\n* Minimum 3 months of follow-up data available\n\nExclusion Criteria:\n\n* Participation in an interventional clinical trial for first-line therapy\n* Insufficient treatment or follow-up data for analysis\n* DRd used in relapsed\u002Frefractory setting rather than newly diagnosed disease",{"count":236,"type":22},300,"OBSERVATIONAL","This study will describe the use of triplet therapy with daratumumab, lenalidomide and dexamethasone (DRd) in the treatment of for transplant ineligible (TIE) untreated myeloma outside of clinical trials and assess the associated clinical outcomes.",[36],"2026-04-15",{"date":242,"type":48},"2026-04-20",{"date":244,"type":22},"2026-07",{"date":51,"type":22},{"name":247,"class":54},"The Royal Wolverhampton Hospitals NHS Trust",{"id":249,"slug":250,"hasResults":12,"nctId":251,"briefTitle":252,"officialTitle":253,"acronym":254,"eligibilityCriteria":255,"healthyVolunteers":12,"sex":18,"minAge":256,"maxAge":257,"enrollmentInfo":258,"targetDuration":4,"studyType":23,"phases":260,"briefSummary":261,"conditions":262,"keywords":266,"overallStatus":188,"whyStopped":4,"lastUpdateSubmitDate":270,"lastUpdatePostDateStruct":271,"startDateStruct":273,"completionDateStruct":275,"leadSponsor":277,"locationsCount":279},"100615788","phase-1-cd70car-for-cd70-lymphoma-myeloma-and-solid-tumors-100615788","NCT07297160","CD70.CAR for CD70+ Lymphoma, Myeloma and Solid Tumors","Chimeric Antigen Receptor Treatment Targeting Lymphoma, Myeloma and Solid Tumors That Express CD70 (SEventY) CALySSEY","CALySSEY","PROCUREMENT INCLUSION CRITERIA:\n\n• Diagnosis of relapsed\u002Frefractory T-cell acute lymphoblastic lymphoma (T-LLy), or T-non-Hodgkin Lymphoma (T-NHL, including Angioimmunoblastic T-cell lymphoma (AITL), Enteropathy-associated T-cell lymphoma (EATL), Monomorphic epitheliotropic intestinal T-cell lymphoma (MEITL), Peripheral T-cell lymphoma (PTCL) NOS, Anaplastic large cell lymphoma (ALCL), Adult T-cell lymphoma (lymphoma or chronic subtypes, Extranodal NK\u002FT cell lymphoma, Mycosis fungoides (excluding Sezary Syndrome Stage IIB or higher) or multiply relapsed Hodgkin Lymphoma\n\nOR\n\nPatients with relapsed\u002Frefractory Renal Cell Carcinoma (RCC) OR sarcomas (for sarcoma only patients age 25 or younger are eligible)\n\nOR\n\nPatients with relapsed or refractory multiple myeloma (MM) that have failed or are ineligible for the 3 main classes of MM therapy (\"triple class refractory\")\n\n(3 classes: 1. Immunomodulatory drugs, 2. proteosome inhibitors and 3. Anti-CD38 monoclonal antibodies).\n\n* CD70 positive tumor with at least 26% CD70+ tumor cells by immunohistochemistry (staining can be pending at time of procurement)\n* Age ≤75 years (except for sarcoma: only patients age ≤25 are eligible) NOTE: The first three (3) patients treated on the study will be adults (≥18 years of age)\n* Hemoglobin ≥ 7.0 g\u002FdL (can be transfused)\n* If apheresis required to collect blood, PT and aPTT \\\u003C1.5x ULN; Serum Creatinine \\\u003C 2 x ULN; AST \\\u003C 5 x ULN.\n\nPROCUREMENT EXCLUSION CRITERIA:\n\n* Active infection (bacterial, fungal or viral) requiring ongoing treatment without improvement.\n* Known active infection with HIV or HTLV (collected blood will be sent for HIV\u002FHTLV testing, separate testing prior to procurement not required). Patients with HIV are eligible if viral load is undetectable on therapy and CD4 count is \\>350 mm3.\n* Active second cancer (except non-melanoma skin cancer or in situ breast cancer or cervical cancer) or other cancer treated ≤ 2 years prior to enrollment\n* Ongoing treatment with immune suppression for prophylaxis\u002Ftreatment of GVHD including high dose steroids (e.g., prednisone \\> 0.5 mg\u002Fkg\u002Fday).\n\nTREATMENT INCLUSION CRITERIA:\n\n• Diagnosis of relapsed\u002Frefractory T-cell acute lymphoblastic lymphoma (T-LLy), or T-non-Hodgkin Lymphoma (T-NHL, including Angioimmunoblastic T-cell lymphoma (AITL), Enteropathy-associated T-cell lymphoma (EATL), Monomorphic epitheliotropic intestinal T-cell lymphoma (MEITL), Peripheral T-cell lymphoma (PTCL) NOS, Anaplastic large cell lymphoma (ALCL), Adult T-cell lymphoma (lymphoma or chronic subtypes), , Extranodal NK\u002FT cell lymphoma, Mycosis fungoides (excluding Sezary Syndrome Stage IIB or higher) or multiply relapsed Hodgkin Lymphoma\n\nOR\n\nPatients with relapsed\u002Frefractory Renal Cell Carcinoma (RCC) or sarcomas (for sarcoma only patients age 25 or younger are eligible)\n\nOR\n\nPatients with relapsed or refractory multiple myeloma (MM) that have failed or are ineligible for the 3 main classes of MM therapy (\"triple class refractory\") and also failed or ineligible for anti-BCMA therapies.\n\n(3 classes: 1. Immunomodulatory drugs, 2. proteosome inhibitors and 3. Anti-CD38 monoclonal antibodies).\n\n* CD70 positive tumor with at least 26% CD70+ tumor cells by immunohistochemistry (tissue)\n* No systemic chemotherapy at least 2 weeks prior to treatment on study and must be recovered from all acute toxic effects of prior chemotherapy at time of treatment\n* Age ≤75 years. (except for sarcoma: only patients age ≤25 are eligible) NOTE: The first three (3) patients treated on the study will be adults (≥18 years of age).\n* Hemoglobin ≥ 7.0 g\u002FdL (can be transfused)\n* Total bilirubin \\\u003C 3 times the upper limit of normal\n* AST\u002FALT \\\u003C 5 times the upper limit of normal\n* Creatinine \\\u003C 2 times the upper limit of normal\n* Pulse oximetry of \\> 90% on room air\n* Karnofsky or Lansky score of ≥60%\n* Sexually active patients must be willing to utilize one of the more effective birth control methods during the study and for 6 months after the study is concluded. Male partner should use a condom.\n* Informed Consent Obtained.\n\nTREATMENT EXCLUSION CRITERIA:\n\n* Received investigational anti-cancer agents \\\u003C 28 days or 5 half-lives, whichever is shorter\n* Received any tumor vaccines within the previous 6 weeks\n* Pregnant or lactating\n* Uncontrolled infection with HIV, or HTLV. Patients with HIV are eligible if viral load is undetectable on therapy and CD4 count is \\>350 mm3.\n* Clinically significant bacterial, fungal, or viral infection requiring ongoing therapy without improvement.\n* Cardiac abnormalities: Cardiac echocardiography with LVEF\\\u003C50%; Cardiac dysfunction NYHA III or IV; Clinically significant pericardial effusion. Confirmation of absence of these conditions must be obtained within 6 months of treatment.\n* Use of serotherapy with Campath or Anti-Thymocyte Globulin (ATG) within the last 28 days\n* Use of Donor Lymphocyte Infusion (DLI) or other cellular therapy product within 28 days.\n* Acute GVHD ≥ Grade 2 or moderate to severe (formerly extensive) chronic GVHD.\n* High dose steroids \\>1 mg\u002Fkg within the preceding 5 days or currently receiving \\>0.5 mg\u002Fkg\u002Fday prednisone equivalent.\n* Bulky CNS or mediastinal disease that significantly increases potential risks (e.g. airway obstruction, TIAN) in the estimation of a principal investigator.","0 Years","75 Years",{"count":259,"type":22},88,[66],"This study is for patients who have a type of cancer that expresses the protein CD70, which includes lymphoma (lymph gland cancer), myeloma and solid tumors including some sarcomas and kidney cancers, and the cancer has come back or has not gone away after standard of care treatment.\n\nAs there are limited or no remaining standard treatments available to treat this cancer, patients are being asked to volunteer to be in a gene transfer research study using special immune cells to create a specialized immune cell that will recognize a protein called CD70 that is expressed on the outside surface of the tumor cells in the body.\n\nThis research study combines different ways of fighting disease by using T cells and \"arming\" them to recognize a specific protein on cancer cells. T cells, also called T lymphocytes, are special infection-fighting blood cells that can kill other cells including tumor cells. T cells by themselves have been used to treat patients with cancers and have shown promise, but have not been strong enough to cure most patients.\n\nThe protein used in this study is called anti-CD70. It has been developed from human CD27 on normal T cells, since it is the natural binding partner that can connect with CD70. This anti-CD70 protein sticks to tumor cells when it binds to CD70. CD70 binders have been used to treat people with different types of cancers. For this study, anti-CD70 has been changed so that instead of floating free in the blood it is now joined to the T cells. When binder is joined to a T cell in this way it is called a chimeric receptor or \"CAR T cell\". The doctors then made another change to cause these T cells to kill any cell that has CD70. This causes the \"CAR T cells\" to kill blood cancer cells which are confirmed to have CD70.\n\nIn the laboratory, investigators have found that T cells work better if there are proteins added that stimulate T cells. The anti-CD70 (CD27) protein is unique because it can bind to CD70 on tumor cells but also stimulates the T cells that express it. Adding the CD27 makes the cells grow better and may help them to last longer in the body, thus giving the cells a better chance of killing the tumor cells.\n\nThese CD70 \"CAR\" T cells are investigational products not approved by the Food and Drug Administration.\n\nThe purpose of this study is to find a dose of CAR T cells that is safe, to learn what the side effects are and to see whether this therapy might help people with lymphoma (lymph gland cancer), myeloma and certain solid tumors including some sarcomas and kidney cancers.",[160,36,263,264,265],"Solid Tumors","Sarcoma","Kidney Cancer",[160,36,263,267,268,159,269],"T cell","CD70.CAR T-cells","Lymph Gland Cancer","2026-03-03",{"date":272,"type":48},"2026-03-04",{"date":274,"type":22},"2026-06",{"date":276,"type":22},"2044-12",{"name":278,"class":78},"Baylor College of Medicine",2,{"id":281,"slug":282,"hasResults":12,"nctId":283,"briefTitle":284,"officialTitle":285,"acronym":4,"eligibilityCriteria":286,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":287,"targetDuration":4,"studyType":23,"phases":289,"briefSummary":290,"conditions":291,"keywords":293,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":295,"lastUpdatePostDateStruct":296,"startDateStruct":298,"completionDateStruct":300,"leadSponsor":302,"locationsCount":226},"100496519","leukemia-and-lymphoma-society-lls-services-impact-on-outcomes-and-care-100496519","NCT05745285","Leukemia and Lymphoma Society (LLS) Services Impact on Outcomes and Care","The Impact of a Non-Profit Cancer Advocacy Organization on Patient Reported Outcomes and Access to Care: A Multisite, Longitudinal Trial","Inclusion Criteria:\n\n* Be diagnosed with, or have a recurrence of leukemia, lymphoma, myeloma, myelodysplastic syndromes (MDS), or myeloproliferative neoplasms (MPN).\n* Have received, be receiving, or be planning to receive primary or relapse treatment for leukemia, lymphoma, myeloma, myelodysplastic syndromes (MDS), or myeloproliferative neoplasms (MPN) and meet at least one of the following criteria:\n\n  * Be currently receiving treatment which started within the past 18 months OR\n  * Be planning to start treatment within one month OR\n  * Have received Bone Marrow Transplant or CAR-T cell therapy within the past 100 days.\n* Not be currently participating in any LLS programs or services\n* Be willing to be followed for 6 months\n* Speak English or Spanish\n\nExclusion Criteria:\n\n* Are not diagnosed with, or have a recurrence of leukemia, lymphoma, myeloma, myelodysplastic syndromes (MDS), or myeloproliferative neoplasms (MPN)\n* Do not meet at least one of the following criteria if treated or planning to get treated for leukemia, lymphoma, myeloma, myelodysplastic syndromes (MDS), or myeloproliferative neoplasms (MPN):\n\n  * Be currently receiving treatment which started within the past 18 months OR\n  * Be planning to start treatment within one month OR\n  * Have received Bone Marrow Transplant or CAR-T cell therapy within the past 100 days.\n* Are currently participating in any LLS programs or services\n* Are not willing to be followed for 6 months\n* Do not speak English or Spanish.",{"count":288,"type":22},400,[25],"The purpose of this study is to learn about the impact that the services and programs provided by Blood Cancer United (formerly, The Leukemia and Lymphoma Society) have among patients with blood cancer, such as access to care, quality of life, and financial burden.",[161,160,36,94,292],"Myeloproliferative Neoplasm",[294],"Blood cancer","2026-02-18",{"date":297,"type":48},"2026-02-20",{"date":299,"type":48},"2025-02-04",{"date":301,"type":22},"2026-11-01",{"name":303,"class":78},"University of Miami",{"id":305,"slug":306,"hasResults":12,"nctId":307,"briefTitle":308,"officialTitle":308,"acronym":4,"eligibilityCriteria":309,"healthyVolunteers":12,"sex":18,"minAge":310,"maxAge":4,"enrollmentInfo":311,"targetDuration":4,"studyType":23,"phases":313,"briefSummary":314,"conditions":315,"keywords":4,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":318,"lastUpdatePostDateStruct":319,"startDateStruct":321,"completionDateStruct":323,"leadSponsor":325,"locationsCount":55},"100622934","multimodal-telerehabilitation-in-patients-undergoing-car-t-cell-immunotherapy-100622934","NCT07390071","Multimodal Telerehabilitation in Patients Undergoing CAR-T Cell Immunotherapy","Inclusion Criteria:\n\n* age \\>21\n* confirmed diagnosis of lymphoma or myeloma\n* commercial FDA-approved CAR-T delivery planned for ≥4 weeks following enrollment\n* Eastern Cooperative Oncology Group (ECOG) performance status 0-2.\n* Access to a working telephone line in their home or a cell phone.\n\nExclusion Criteria:\n\n* have unstable angina, uncontrolled hypertension, recent myocardial infarction, pacemakers, painful or unstable bony metastases, or recent skeletal fractures;\n* are engaged in a regular exercise rehabilitation program;\n* have relocation plans within next 6 months;\n* participate in another clinical trial.","21 Years",{"count":312,"type":22},40,[25],"The proposed multimodal telerehabilitation model allows a rehabilitation therapy team to set up individualized rehabilitation plans using a web-based care management portal and monitor patient progress online. Patients at home follow a safe and effective personalized exercise and nutrition plan guided by interactive touch-screen technology combined with behavioral counseling, social support, and interactive education and empowerment. The design of the telerehabilitation system is based on the cloud-based Internet-of-Things architecture allowing real-time monitoring of cardiovascular parameters and exercise performance. The patient's level of exertion during exercise is automatically identified by a validated AI-driven algorithm supporting exercise safety and efficacy. The ultimate goal of this pilot feasibility project is to establish the extent of the impact of the proposed patient-centered cancer telerehabilitation model on disease-specific quality of life, and functional and symptom outcomes and to obtain sufficient evidence for a definitive randomized clinical trial evaluating this approach in a multi-center study.",[160,36,316,317],"Cytokine Release Syndrome","Immune Effector Cell Associated Neurotoxicity Syndrome","2026-01-28",{"date":320,"type":48},"2026-02-05",{"date":322,"type":48},"2025-09-01",{"date":324,"type":22},"2029-01",{"name":326,"class":78},"University of Utah",{"id":328,"slug":329,"hasResults":12,"nctId":330,"briefTitle":331,"officialTitle":331,"acronym":332,"eligibilityCriteria":333,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":334,"targetDuration":4,"studyType":23,"phases":336,"briefSummary":337,"conditions":338,"keywords":4,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":339,"lastUpdatePostDateStruct":340,"startDateStruct":342,"completionDateStruct":344,"leadSponsor":346,"locationsCount":279},"100383097","phase-2-a-multicentre-non-blinded-study-exploring-self-administration-of-chemotherapy-in-the-home-environment-100383097","NCT04268199","A Multicentre, Non-Blinded Study Exploring Self-Administration of Chemotherapy in the Home Environment","EASE","Inclusion Criteria:\n\n* Patients are aged 18 years old or older with a diagnosis of symptomatic myeloma,\n* Stable clinical status as deemed by responsible investigator,\n* Personally (or caregiver) willing and deemed capable to self-administer with teaching,\n* Previously received more than 4 injections of bortezomib within the hospital and\u002For cancer centre environment,\n* Signed informed consent.\n\nExclusion Criteria:\n\n* Currently participating in clinical trials that includes the use of bortezomib,\n* History of allergic reactions to bortezomib,\n* History of bleeding attributable to bortezomib,\n* History of greater than or equal to grade 3 side effects attributable to bortezomib,\n* Clinically deemed unlikely to be compliant with therapy by responsible investigator,\n* Life expectancy anticipated to be less than 6 months,\n* Deemed geographically inaccessible to receive care.",{"count":335,"type":22},100,[90],"This study is to see if the standard of care subcutaneous injection of bortezomib can safely be administered at home by the patient or caregiver. All tests and assessments are based on standard of care procedures.",[36,127],"2025-12-08",{"date":341,"type":48},"2025-12-15",{"date":343,"type":48},"2020-05-29",{"date":345,"type":22},"2026-12",{"name":347,"class":78},"AHS Cancer Control Alberta",{"id":349,"slug":350,"hasResults":12,"nctId":351,"briefTitle":352,"officialTitle":353,"acronym":4,"eligibilityCriteria":354,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":355,"targetDuration":4,"studyType":23,"phases":357,"briefSummary":358,"conditions":359,"keywords":361,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":365,"lastUpdatePostDateStruct":366,"startDateStruct":368,"completionDateStruct":370,"leadSponsor":372,"locationsCount":226},"100555935","phase-1-elotuzumab--iberdomide--dexamethasone-post-ide-cel-in-rrmm-100555935","NCT06518551","Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM","A Phase I\u002FII Study of Elotuzumab and Iberdomide and Dexamethasone Post Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma","Inclusion Criteria:\n\n* Previously diagnosed with MM based on standard IMWG criteria\n* Patient has given voluntary written informed consent before any study-related procedures not part of normal medical care are performed, with the understanding that consent may be withdrawn by the patient at any time without prejudice to their future medical care.\n* Patient who has been treated with at least 4 prior lines of anti-myeloma treatment including immunomodulating agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody.\n* In addition, to at least 4 prior lines of anti-myeloma treatment, patient has received ide-cel in accordance with the FDA approved US Prescribing Information and has achieved at least a partial response, and is within 90 days of infusion\n* ECOG performance status ≤2 (Karnofsky ≥60%, see Appendix A)\n* Screening Laboratory evaluations within the following parameters\n\n  * Absolute neutrophil count (ANC) ≥ 1,000 cells\u002FdL (1.0 x 109\u002FL) (Growth factors cannot be used more recently than 7 days prior to initiation of therapy)\n  * Platelet count ≥ 75,000 cells\u002FdL (75 x 109\u002FL) (without transfusions during the 7 days prior to initiation of therapy)\n  * Hemoglobin ≥ 8.0 g\u002FdL (RBC transfusions are permitted)\n  * Total Bilirubin ≤ 1.5 X upper limit of normal (ULN) (except subjects with Gilbert Syndrome, who can have total bilirubin \\\u003C 3.0 mg\u002FdL)\n  * AST or ALT ≤ 3x ULN\n  * Creatinine clearance ≥ 30 ml\u002Fmin according to the Cockroft-Gault formula:\n\n    * Female CrCl = \\[(140 - age in years) x weight in kg x 0.85\\] \u002F \\[72 x serum creatinine in mg\u002FdL\\]\n    * Male CrCl = \\[(140 - age in years) x weight in kg x 1.00\\] \u002F \\[72 x serum creatinine in mg\u002FdL\\]\n* Age ≥18 years.\n* Ability to understand and the willingness to sign a written informed consent document.\n* A Female of childbearing potential (FCBP) must:\n\n  * Have two negative pregnancy tests before enrollment and randomization into the clinical studies and prior to each re-supply of study drug during the clinical studies based on the frequency outlined in the Pregnancy Prevention Plan (PPP, Appendix D).\n  * Sexually active FCBP must agree to use protocol-specified contraceptive methods during participation in the clinical studies and for at least 28 days after the last dose of study drug.\n* Sexually active males (including those who have had a vasectomy) must agree to use protocol specified contraceptive methods during participation in the clinical studies and for at least 28 days after the last dose of study drug.\n* All participants (male and female with or without childbearing potential) must agree to abstain from donating blood products for at least 28 days after the last dose of study drug and semen or sperm while taking study drug and for at least 28 days after the last dose of study drug.\n\nExclusion Criteria\n\n* Prior exposure to Iberdomide\n* Participation in other clinical trials, including those with other investigational agents not included in this trial, within 30 days of the start of this trial and throughout the duration of this trial.\n* Diagnosed or treated for another malignancy within 3 years prior to enrollment, with the exception of complete resection of basal cell carcinoma or squamous cell carcinoma of the skin, an in-situ malignancy, or low risk prostate cancer after curative therapy\n* Known central nervous system involvement.\n* Systemic treatment, within 14 days before the first dose of treatment, with strong CYP3A or inducers (rifampin, rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital), or use of St. John's wort OR systemic treatment within 14 days of the first dose of treatment with a strong inhibitor of CYP1A2 (ciprofloxacin, fluvoxamine, cimetidine, enoxacin, ethynyl estradiol, mexiletine)\n* Any medical or psychiatric illness\u002Fsocial situation that in the Investigator's opinion, would impose excessive risk to the patient, would adversely affect his\u002Fher participating in this study or would limit compliance with study requirements.\n* Currently active graft versus host disease of any stage or grade after allogeneic stem cell transplantation\n* Prior major surgical procedure or radiation therapy within 14 days of initiation of therapy.\n\n  * Those who require a limited course of radiation for management of bone pain more than 14 days out from initiation of therapy are not excluded\n* Any active, or uncontrolled cardiovascular conditions, including but not limited to uncontrolled hypertension, uncontrolled cardiac arrhythmias, symptomatic congestive heart failure, unstable angina, grade 3 thromboembolic event or myocardial infarction within the past 6 months.\n* The following therapies within the stated time frames prior to initiation of therapy:\n\n  * Previous cytotoxic therapies, including cytotoxic investigational agents, for multiple myeloma within 21 days (42 days for nitrosoureas).\n  * The use of live vaccines within 30 days.\n  * IMiDs or proteasome inhibitors within 14 days.\n  * Other investigational therapies and\u002For monoclonal antibodies within 4 weeks.\n  * Prior peripheral stem cell transplant within 12 weeks.\n  * Prior allogeneic stem cell transplantation with active graft-versus-host-disease.\n* Those who require a limited course of daily requirement for corticosteroids (equivalent to \\>10 mg\u002Fday prednisone, though \\>10mg\u002Fday is acceptable if physiological levels require, so long as the dose is stable for at least 7 days prior to initiation of therapy. Inhalation corticosteroids are exempt from this criterion.\n\n  * Lower amounts of corticosteroids that are not part of a daily requirement within 14 days prior to initiating therapy\n* Concurrent symptomatic amyloidosis or plasma cell leukemia\n* POEMS syndrome (plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, monoclonal protein and skin changes)\n* Infection requiring systemic antibiotic therapy or other serious infection within 7 days of starting therapy.\n\n  * Those who are on prophylactic antibiotics only, or on antibiotics and have confirmation of resolution of active infection are eligible.\n* Known seropositive for active viral infection with human immunodeficiency virus (HIV) hepatitis B (HBV) or hepatitis C viral (HCV). Those who are seropositive because of hepatitis B vaccine are eligible. Patients who are positive for HBV core antibody or HBV surface antigen must have a negative polymerase chain reaction (PCR) result prior to enrollment. Those who are PCR positive will be excluded\n* Female patients who are pregnant or lactating.\n* Participants who are receiving any other investigational agents for any indication\n* History of erythema multiforme or severe hypersensitivity to prior IMiD's® or those who have a known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent.\n* Inability to tolerate thromboprophylaxis\n* Failure to have fully recovered (≤ Grade 2 according to CTCAE v 5) from the reversible effects of prior chemotherapy",{"count":356,"type":22},49,[66,90],"The aim of this research study is to evaluate the efficacy of Elotuzumab and Iberdomide therapy post-Idecabtagene Vicleucel in participants with relapsed and refractory multiple myeloma.\n\nThe names of the study drugs involved in this study are:\n\n* Iberdomide (a type of cereblon E3 ligase modulator)\n* Elotuzumab (a type of monoclonal antibody)\n* Dexamethasone (a type of steroid)",[36,126,360],"Refractory Multiple Myeloma",[36,126,360,362,363,364],"Relapsed Multiple Myeloma","Relapsed and Refractory Multiple Myeloma","MM","2025-12-04",{"date":367,"type":48},"2025-12-11",{"date":369,"type":48},"2024-11-01",{"date":371,"type":22},"2034-12-31",{"name":373,"class":78},"Omar Nadeem, MD",{"id":375,"slug":376,"hasResults":12,"nctId":377,"briefTitle":378,"officialTitle":379,"acronym":4,"eligibilityCriteria":380,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":381,"targetDuration":4,"studyType":23,"phases":383,"briefSummary":384,"conditions":385,"keywords":4,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":386,"lastUpdatePostDateStruct":387,"startDateStruct":389,"completionDateStruct":391,"leadSponsor":392,"locationsCount":55},"100588874","phase-2-elranatamab-post-cilta-cel-in-patients-with-clinical-high-risk-relapsed-myeloma-100588874","NCT06947083","Elranatamab Post Cilta-cel in Patients With Clinical High Risk Relapsed Myeloma","Phase II Study of Elranatamab as Maintenance Therapy Post Ciltacabtagene-autoleucel(Cilta-cel) in Patients With Clinical High Risk Relapsed Myeloma","Inclusion Criteria:\n\n* Understand and voluntarily sign an informed consent form.\n* Have received commercial cilta-cel within 3-6 months for relapsed refractory myeloma and have high risk cytogenetics by IMW (del17p, or t(4;14) or t(14;16) or history of EMD, and must not have evidence of progressive disease by IMWG criteria(Appendix B) following CAR-T cell therapy.\n* Have received \\>2 prior treatment regimens including an immunomodulatory drug, a proteasome inhibitor and a CD38 monoclonal antibody.\n* Able to adhere to the study visit schedule and other protocol requirements.\n* Patients must have available clonoseq ID prior to enrollment to track MRD status.\n* Eastern Cooperative Group (ECOG) Performance Status of 0 or 1.\n* Serum bilirubin levels ≤1.5 times the upper limit of the normal range for the laboratory (ULN), unless related to Gilbert syndrome.\n* Serum AST or serum ALT levels ≤2 x ULN.\n* Must have adequate bone marrow function.\n\nExclusion Criteria:\n\n* Ongoing active infection defined as an infection that is worsening despite therapy and causing symptoms or requiring intravenous antibiotic treatment.\n* Ongoing CRS or ICANS of any grade.\n* Active plasma cell leukemia.\n* Patients with CNS involvement, including meningeal involvement.\n* Patients with history of Guillain-Barre syndrome.\n* Uncontrolled medical problems such as diabetes mellitus, congestive heart failure, coronary artery disease, hypertension, unstable angina, arrhythmias), pulmonary, hepatic and renal diseases unless renal insufficiency is felt to be secondary to multiple myeloma, which in the opinion of the treating physician pose an unacceptable risk to the patient.\n* Pregnant or lactating females.\n* Concurrent use of other anti-cancer agents or treatments.\n* Known seropositive for or active viral infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV). Patients who are seropositive because of hepatitis B virus vaccine are eligible. Note: patients with hepatitis C previously treated with curative intent are considered eligible.\n* Patients with renal failure requiring dialysis.",{"count":382,"type":22},39,[90],"The purpose of the study is to evaluate the effect of Elranatamab therapy after cilta-cel measuring how long a patient with high risk relapsed myeloma lives without the myeloma getting worse(progressing), also known as progression-free survival (PFS). Patients with clinical high-risk myeloma, defined as having history of myeloma that has grown outside of the bones or having high risk mutations in the myeloma cells, benefit less from cilta-cel compared to myeloma patients without these characteristics.",[36],"2025-12-02",{"date":388,"type":48},"2025-12-03",{"date":390,"type":48},"2025-05-27",{"date":223,"type":22},{"name":393,"class":78},"H. Lee Moffitt Cancer Center and Research Institute",{"id":395,"slug":396,"hasResults":12,"nctId":397,"briefTitle":398,"officialTitle":398,"acronym":399,"eligibilityCriteria":400,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":401,"targetDuration":4,"studyType":237,"phases":4,"briefSummary":403,"conditions":404,"keywords":419,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":427,"lastUpdatePostDateStruct":428,"startDateStruct":430,"completionDateStruct":432,"leadSponsor":434,"locationsCount":55},"100339653","liquid-biopsy-evaluation-and-repository-development-at-princess-margaret-100339653","NCT03702309","Liquid Biopsy Evaluation and Repository Development at Princess Margaret","LIBERATE","Inclusion Criteria:\n\n1. Patients with either histological confirmation of a solid tumor or hematological malignancy, OR patients identified as high-risk for cancer (based on identified aberration in cancer predisposition gene or on hormonal and\u002For family history without known aberration).\n2. Patient must be ≥ 18 years old.\n3. All patients must have signed and dated an informed consent form for this LIBERATE study.\n4. If patients are being co-consented for a separate primary research study listed in Appendix I, they must fulfill the eligibility criteria for that separate primary research study. If there is a discrepancy in the eligibility criteria between protocols, the separate primary research study's criteria take precedence.\n\nExclusion Criteria:\n\nNone",{"count":402,"type":22},2500,"The objective of this protocol is to develop an institution-wide liquid biopsy protocol that will establish a common process for collecting blood and corresponding archived tumor specimens for future research studies at the University Health Network's Princess Margaret Cancer Centre. Circulating cell-free nucleic acids (cfNA), including cell-free DNA (cfDNA) and cell-free RNA (cfRNA), are non-invasive, real-time biomarkers that can provide diagnostic and prognostic information before cancer diagnosis, during cancer treatment, and at disease progression. Cancer research scientists and clinicians at the Princess Margaret are interested in incorporating the collection of peripheral blood samples (\"liquid biopsies\") into research protocols as a means of non-invasively assessing tumor progression and response to treatment at multiple time points during a patient's course of disease.",[405,406,407,408,409,410,160,161,411,412,413,414,415,416,36,265,417,418],"Cancer","Breast Cancer","Lung Cancer","Colon Cancer","Ovarian Cancer","Melanoma","Mutation","Lynch Syndrome","Cowden Syndrome","BRCA1 Mutation","BRCA2 Mutation","Uterine Cancer","Head and Neck Cancer","Meningioma",[420,421,422,423,424,425,263,426],"High Risk","Liquid Biopsy","Circulating Tumor DNA","Blood","Molecular Profiling","Next Generation Sequencing","Hematological","2025-11-25",{"date":429,"type":48},"2025-11-26",{"date":431,"type":48},"2017-08-03",{"date":433,"type":22},"2026-07-06",{"name":435,"class":78},"University Health Network, Toronto",{"id":437,"slug":438,"hasResults":12,"nctId":439,"briefTitle":440,"officialTitle":441,"acronym":4,"eligibilityCriteria":442,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":443,"targetDuration":4,"studyType":23,"phases":445,"briefSummary":447,"conditions":448,"keywords":450,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":461,"lastUpdatePostDateStruct":462,"startDateStruct":464,"completionDateStruct":466,"leadSponsor":468,"locationsCount":226},"100608479","phase-2-role-of-antibiotic-therapy-or-immunoglobulin-on-infections-in-haematology-immunoglobulin-stopping-or-extension-stop-ig-100608479","NCT07202091","Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Immunoglobulin Stopping or Extension (Stop Ig)","Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy (Stop-Ig)","Inclusion Criteria:\n\n1. Patients must be receiving Ig (IV or subcutaneous - SCIg) replacement for prevention of bacterial infections due to hypogammaglobulinaemia for at least 6 consecutive months.\n2. Patient is eligible for trial of Ig cessation in the opinion of the treating clinician and local investigator.\n3. Patient is willing and able to comply with each of the treatment arms.\n\nExclusion Criteria:\n\n1. Prior or planned allogeneic haematopoietic stem cell transplantation.\n2. Major infection (Grade 3 or higher) in preceding 3 months, and\u002For current active infection requiring systemic antimicrobial treatment.\n3. Already receiving systemic antibiotic prophylaxis for the purpose of preventing bacterial infection (NB: patients may receive antiviral, antifungal and PJP prophylaxis).\n4. Intolerance of all trial antibiotic options in either arm A or arm B.\n5. Communication, compliance or logistical issues that are likely to limit patient's ability to take prophylactic or emergency antibiotics, or to obtain urgent medical attention for symptoms of infection.\n6. Pregnant or breastfeeding.\n7. Severe renal impairment (estimated or measured creatinine clearance of \\\u003C 30 mL\u002Fmin).\n8. Previous splenectomy.\n9. Previous participation in this domain.\n10. Treating team deems enrolment in the domain is not in the best interests of the patient.",{"count":444,"type":22},900,[90,446],"PHASE3","This study is being conducted to find out how safe and effective different strategies of infection prevention are in comparison to each other, for preventing infection in patients with blood cancers. The best way to find out this information is to directly compare the effect of different treatment strategies in patients with blood cancers. We want to know how these different treatments impact on your health and your use of healthcare services.\n\nThis research project uses an Adaptive Platform Design. This design allows the researchers to compare multiple infection prevention strategies within the same trial at the same time (rather than running separate trials), to analyse results as the trial occurs and to add new research questions during the course of the trial.\n\nThe treatments that you may receive as part of the study will be determined by which domain(s) of the platform you participate in. By combining data collected within each domain as part of the platform, the researchers can investigate and compare treatment strategies and infection outcomes across a broader range of participants.",[36,161,449],"Non Hodgkin's Lymphoma",[451,452,135,453,454,455,456,457,458,459,460],"immunoglobulin","antibiotics","leukaemia","lymphoma","non Hodgkins","infection","infections","blood","cancer","haematology","2025-10-01",{"date":463,"type":48},"2025-10-07",{"date":465,"type":48},"2025-05-06",{"date":467,"type":22},"2027-03-31",{"name":469,"class":78},"Monash University",{"id":471,"slug":472,"hasResults":12,"nctId":473,"briefTitle":474,"officialTitle":475,"acronym":4,"eligibilityCriteria":476,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":477,"targetDuration":4,"studyType":23,"phases":478,"briefSummary":479,"conditions":480,"keywords":482,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":461,"lastUpdatePostDateStruct":483,"startDateStruct":484,"completionDateStruct":485,"leadSponsor":486,"locationsCount":226},"100608476","phase-2-role-of-antibiotic-therapy-or-immunoglobulin-on-infections-in-haematology-platform-trial-rational-pt-100608476","NCT07202052","Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Platform Trial (RATIONAL-PT)","A Randomised Platform Trial Evaluating the Role of Interventions to Prevent Infection in Patients With Acquired Hypogammaglobulinemia Secondary to Haematological Malignancies - RATIONAL-PT (Core)","Inclusion Criteria:\n\n1. Aged greater than or equal to 18 years of age\n2. Diagnosis of haematological malignancy, including (CLL) chronic lymphocytic leukemia, (MM) multiple myeloma or (NHL) non-Hodgkin's lymphoma.\n3. Eligible to receive or currently receiving Ig (IV or subcutaneous - SCIg) replacement for history of recurrent or severe infection(s) and IgG less than the lower limit of the reference range (excluding paraprotein) OR IgG\\\u003C4g\u002FL (excluding paraprotein)\n4. Life expectancy \\> 12 months\n5. Able to give informed consent\n\nExclusion Criteria:\n\n1\\. Treating team deems enrolment in the study is not in the best interests of the patient.",{"count":444,"type":22},[90,446],"This is an adaptive platform study to find out how safe and effective different strategies are in comparison to each other, for preventing infection in patients with blood cancers.\n\nIt is a comparison between Immunoglobulin and antibiotics use.",[36,481,161],"Non-Hodgkin's Lymphoma",[451,452,135,453,454,455,456,457,458,459,460],{"date":463,"type":48},{"date":465,"type":48},{"date":467,"type":22},{"name":469,"class":78},{"id":488,"slug":489,"hasResults":12,"nctId":490,"briefTitle":491,"officialTitle":492,"acronym":4,"eligibilityCriteria":493,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":494,"targetDuration":4,"studyType":23,"phases":495,"briefSummary":447,"conditions":496,"keywords":497,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":461,"lastUpdatePostDateStruct":498,"startDateStruct":499,"completionDateStruct":501,"leadSponsor":502,"locationsCount":226},"100608478","phase-2-role-of-antibiotic-therapy-or-immunoglobulin-on-infections-in-haematology-starting-immunoglobulin-start-ig-100608478","NCT07202078","Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy: Starting Immunoglobulin (Start Ig)","Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy (Start Ig)","Inclusion Criteria:\n\n* None.\n\nExclusion Criteria:\n\n1. Prior or planned allogeneic haematopoietic stem cell transplantation.\n2. Already receiving systemic antibiotic prophylaxis for the purpose of preventing bacterial infection (NB: patients may receive antiviral, antifungal and PJP prophylaxis).\n3. Received immunoglobulin replacement in the preceding three months.\n4. Objection to receiving immunoglobulin products.\n5. Known history of IgA deficiency with anti-IgA.\n6. History of severe allergy to immunoglobulin products.\n7. Current active infection requiring systemic antibiotics.\n8. Allergy or intolerance of all domain antibiotic options.\n9. Pregnant or breastfeeding.\n10. Severe renal impairment (estimated or measured creatinine clearance of \\\u003C 30 mL\u002Fmin).\n11. Previous splenectomy.\n12. Previous participation in this domain.\n13. Treating team deems enrolment in the domain is not in the best interest of the patient.",{"count":444,"type":22},[90,446],[36,449,161],[451,452,135,453,454,455,456,457,458,459,460],{"date":463,"type":48},{"date":500,"type":48},"2025-05-07",{"date":467,"type":22},{"name":469,"class":78},{"id":504,"slug":505,"hasResults":12,"nctId":506,"briefTitle":507,"officialTitle":508,"acronym":4,"eligibilityCriteria":509,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":510,"targetDuration":4,"studyType":23,"phases":511,"briefSummary":447,"conditions":512,"keywords":513,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":461,"lastUpdatePostDateStruct":514,"startDateStruct":515,"completionDateStruct":517,"leadSponsor":518,"locationsCount":226},"100608477","phase-2-role-of-antibiotic-therapy-or-immunoglobulin-on-infections-in-haematology-dosing-immunoglobulin-dose-ig-100608477","NCT07202065","Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Dosing Immunoglobulin (Dose Ig)","Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy (Dose-Ig)","Inclusion Criteria:\n\n1. Patients must be receiving IVIg replacement at standard dose for prevention of bacterial infections due to hypogammaglobulinaemia for at least 6 consecutive months.\n2. Patient is not eligible for trial of Ig cessation in the opinion of the treating clinician and local investigator.\n\nExclusion Criteria:\n\n1. Prior or planned allogeneic haematopoietic stem cell transplantation.\n2. Major infection (Grade 3 or higher) in preceding 3 months, and or current active infection requiring systemic antimicrobial treatment.\n3. Previous splenectomy.\n4. Known history of bronchiectasis.\n5. Previous participation in this domain.\n6. Treating team deems enrolment in the domain is not in the best interest of the patient.",{"count":444,"type":22},[90,446],[36,449,161],[451,452,135,453,454,455,456,457,458,459,460],{"date":463,"type":48},{"date":516,"type":48},"2025-04-28",{"date":467,"type":22},{"name":469,"class":78},{"id":520,"slug":521,"hasResults":12,"nctId":522,"briefTitle":523,"officialTitle":524,"acronym":4,"eligibilityCriteria":525,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":526,"targetDuration":4,"studyType":23,"phases":528,"briefSummary":529,"conditions":530,"keywords":533,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":534,"lastUpdatePostDateStruct":535,"startDateStruct":537,"completionDateStruct":539,"leadSponsor":541,"locationsCount":279},"100553527","heme-home-transfusion-program-100553527","NCT06487247","HEME Home Transfusion Program","Supportive Transfusion Program for Patients With Hematologic Malignancies: A Cluster Randomized Trial","Inclusion Criteria for Patient Participants:\n\n* Diagnosis of a relapsed\u002Frefractory hematologic malignancy\n* Age ≥ 18 years\n* Receipt of primary oncologic care at DFCI (at least 2 outpatient visits in 12 months prior to enrollment)\n* Has received at least one red blood cell (RBC) or platelet transfusion since blood cancer diagnosis in the clinic or hospital setting without a severe transfusion reaction\n* Patient resides within catchment served by Care Dimensions Hospice\n* Physician-estimated prognosis of six months or less\n\nInclusion Criteria for Caregivers:\n\n* Identified informal caregiver of enrolled patient with hematologic malignancy\n* Age ≥ 18 years\n\nExclusion Criteria for Patient Participants:\n\n* Age \\\u003C 18 years\n* Already enrolled in hospice\n* Resides in nursing home or assisted living facility\n* History of previous serious adverse transfusion reaction\n\nExclusion Criteria for Caregivers:\n\n-Age \\\u003C 18 years",{"count":527,"type":22},700,[25],"This research study is evaluating whether a new care delivery program that provides access to home blood transfusions in hospice (i.e, HEME-Hospice) compared to regular standard of care improves quality of life, mood, and end-of-life health care utilization for patients with hematologic malignancies.",[161,36,94,531,532,160],"Hematologic Malignancy","Hematologic Diseases",[161,36,94,531,532,160],"2025-09-15",{"date":536,"type":48},"2025-09-17",{"date":538,"type":48},"2025-09-10",{"date":540,"type":22},"2029-05-31",{"name":542,"class":78},"Dana-Farber Cancer Institute",{"id":544,"slug":545,"hasResults":12,"nctId":546,"briefTitle":547,"officialTitle":548,"acronym":4,"eligibilityCriteria":549,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":550,"targetDuration":4,"studyType":23,"phases":551,"briefSummary":552,"conditions":553,"keywords":4,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":555,"lastUpdatePostDateStruct":556,"startDateStruct":558,"completionDateStruct":560,"leadSponsor":562,"locationsCount":55},"100601144","phase-2-a-phase-ii-study-of-siltuximab-for-crsicans-after-car-t-in-multiple-myeloma-100601144","NCT07106671","A Phase II Study of Siltuximab for CRS\u002FICANs After CAR-T in Multiple Myeloma","A Prospective, Single-Arm, Single-Center, Phase II Clinical Trial of Siltuximab for Cytokine Release Syndrome and Immune Effector Cell-Associated Neurotoxicity After CAR-T Treatment in Multiple Myeloma","Inclusion Criteria:\n\n1. Be informed and voluntarily sign the Informed Consent Form (ICF).\n2. Age ≥18 years old.\n3. Diagnosed with multiple myeloma according to IMWG diagnostic criteria.\n4. Developed CRS (grade ≥1) and\u002For ICANS (grade ≥1) after CAR-T treatment.\n\nExclusion Criteria:\n\n1. Creatinine clearance \\\u003C30 mL\u002Fmin.\n2. Platelet count \\\u003C75,000\u002FμL, absolute neutrophil count \\\u003C1,000\u002FμL, or hemoglobin \\\u003C60 g\u002FL at screening.\n3. ALT or AST \\>3× ULN, or bilirubin \\>2× ULN.\n4. Known severe cardiac conditions, including NYHA class III\u002FIV heart failure, uncontrolled angina, arrhythmia, or hypertension, myocardial infarction within 6 months, or other uncontrolled\u002Fsevere cardiovascular diseases, including prior cerebrovascular events with residual deficits.\n5. Severe comorbidities, including active infections, known active HBV\u002FHCV, HIV infection, uncontrolled diabetes, or serious conditions like chronic restrictive lung disease or cirrhosis.\n6. Known intolerance to Siltuximab.\n7. Known central nervous system (CNS) involement.",{"count":113,"type":22},[90],"This is a prospective Phase II study evaluating Siltuximab for CRS and ICANS after CAR-T infusion in multiple myeloma patients.",[554,36],"CRS - Cytokine Release Syndrome","2025-07-30",{"date":557,"type":48},"2025-08-06",{"date":559,"type":22},"2025-08-10",{"date":561,"type":22},"2027-08-01",{"name":563,"class":78},"Institute of Hematology & Blood Diseases Hospital, China",{"id":565,"slug":566,"hasResults":12,"nctId":567,"briefTitle":568,"officialTitle":569,"acronym":570,"eligibilityCriteria":571,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":572,"targetDuration":4,"studyType":23,"phases":573,"briefSummary":574,"conditions":575,"keywords":576,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":580,"lastUpdatePostDateStruct":581,"startDateStruct":583,"completionDateStruct":585,"leadSponsor":587,"locationsCount":55},"100549186","phase-2-pronto-trial-prophylactic-versus-on-demand-use-of-tocilizumab-100549186","NCT06430736","PRONTO Trial (PRophylactic Versus ON-demand Use of TOcilizumab)","Prospective Comparison Between Prophylactic and On-demand Use of Tocilizumab in CAR-T Recipients - a Randomized, Two Arm, Open-label, Single-center Trial","PRONTO","Inclusion Criteria:\n\n* Patients planned to receive commercial CAR-T treatment for all registered indications comprising lymphomas, leukemias or myeloma at a single academic center (Bern Inselspital)\n* With written informed consent\n* Considered by the investigator to be clinically fit for this treatment\n* Patients aged ≥18 years\n\nExclusion Criteria:\n\n* Previous Tocilizumab treatment within 3 months prior to CAR-T infusion\n* Patients with treatment with an investigational compound within 8 weeks prior to CAR-T infusion\n* Women who are pregnant or breast feeding, or women intending to become pregnant during the study period; or participants lacking safe contraception, defined as: Female participants of childbearing potential, not using and not willing to continue using a medically reliable method of contraception for the entire study duration, such as oral, injectable, or implantable contraceptives, or intrauterine contraceptive devices, or who are not using any other method considered sufficiently reliable by the investigator in individual cases during study treatment and for a total of 12 months; Female participants who are surgically sterilised \u002F hysterectomised or post-menopausal for longer than 2 years are not considered as being of child bearing potential.\n* Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the participant\n* Previous enrolment into the current study\n* Enrolment of the investigator, his\u002Fher family members, employees and other dependent persons",{"count":335,"type":22},[90],"Despite the consequent use of Tocilizumab together with conventional antipyretics at early\u002Ffirst signs of emerging CRS, CRS (and eventually the subsequent development of ICANS) remain a major concern for patients.\n\nThis study aims to identify safety and efficacy of prophylactic Tocilizumab treatment. In particular, to explore whether prophylactic Tocilizumab treatment can decrease the incidence and severity of CRS (and subsequent eventual neurotoxicity) following CAR-T-treatment.",[36,160,161],[577,36,161,160,578,579],"Tocilizumab","CRS","ICANS","2024-07-04",{"date":582,"type":48},"2024-07-08",{"date":584,"type":48},"2024-07-01",{"date":586,"type":22},"2027-06",{"name":588,"class":78},"Insel Gruppe AG, University Hospital Bern",{"id":590,"slug":591,"hasResults":12,"nctId":592,"briefTitle":593,"officialTitle":594,"acronym":595,"eligibilityCriteria":596,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":597,"targetDuration":4,"studyType":23,"phases":599,"briefSummary":600,"conditions":601,"keywords":4,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":602,"lastUpdatePostDateStruct":603,"startDateStruct":605,"completionDateStruct":607,"leadSponsor":609,"locationsCount":174},"100349616","phase-1-evaluation-of-pet-18f-fludarabine-for-the-initial-assessment-and-end-treatment-of-symptomatic-multiple-myeloma-patients-100349616","NCT03832127","Evaluation of PET 18F-Fludarabine for the Initial Assessment and End-treatment of Symptomatic Multiple Myeloma Patients","Exploratory Study Evaluating the Interest of PET to 18F-Fludarabine for the Initial Assessment and End-treatment Evaluation of Patients With Symptomatic Multiple Myeloma in the First Line of Treatment, Not Candidates for Marrow Autograft","Myelofludate","Inclusion Criteria:\n\n* Symptomatic MM in the first line in patients who are not candidates for autologous bone marrow transplantation.\n* Patients eligible for one of the treatments considered as standard in a patient who is not eligible for autograft, according to ESMO's European recommendations\n* MM with measurable disease either by the serum evaluation of the monoclonal component or by the determination of free light chains (serum or urinary).\n* Patient affiliated with a social insurance scheme\n* The patient must understand and voluntarily sign the informed consent form\n* Women of childbearing potential must have a serum pregnancy test (performed within 2 days before each PET scan.)\n* Women of childbearing potential must use an effective contraceptive method throughout the course of the study and for 30 days after the last PET.\n* Male patients (vasectomised or not) with a pregnant partner or a partner of childbearing potential must use a condom and a spermicide until 90 days after the last PET.\n* HIV serology known to be negative\n* Karnofsky ≥ 70 or ECOG 0-1\n\nExclusion Criteria:\n\n* Age under 18 years\n* Pregnancy or breastfeeding\n* Male or female refusing birth control conditions\n* Primary AL amyloidosis and myeloma complicated by amyloidosis\n* Neutropenia \\\u003C1000 PN \u002F mm3\n* Thrombocytopenia \\\u003C70,000 \u002F mm3\n* Hepatic impairment: bilirubin\\> 35μmol \u002F L and SGOT, SGPT, alkaline phosphatase greater than 3 N\n* Renal impairment defined by creatinine clearance \\\u003C50 ml \u002F min\n* History of other malignancies with the exception of basal cell carcinoma and stage I cervical cancer\n* Severe active infection\n* Active infection with known hepatitis B or C virus.\n* Patient with insulin-dependent or non-insulin-dependent diabetes mellitus.\n* Intolerance or known allergy to any of the study drugs or any of its analogues\n* Psychiatric illness that may interfere with participation in the study\n* Patient under safeguard of justice\n* Intellectual inability to sign informed consent\n* Persons protected by law",{"count":598,"type":22},35,[66],"The objective of this exploratory study is to evaluate, for the first time, the sensitivity of 18F-Fludarabine to the initial diagnosis of MM compared to FDG-PET and MRI. The interest of this molecule will also be investigated as part of the end-of-treatment therapeutic evaluation.",[36],"2024-06-12",{"date":604,"type":48},"2024-06-14",{"date":606,"type":48},"2022-09-09",{"date":608,"type":22},"2026-09-09",{"name":610,"class":78},"Nantes University Hospital",{"id":612,"slug":613,"hasResults":12,"nctId":614,"briefTitle":615,"officialTitle":616,"acronym":4,"eligibilityCriteria":617,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":618,"targetDuration":4,"studyType":23,"phases":619,"briefSummary":620,"conditions":621,"keywords":4,"overallStatus":188,"whyStopped":4,"lastUpdateSubmitDate":626,"lastUpdatePostDateStruct":627,"startDateStruct":629,"completionDateStruct":631,"leadSponsor":633,"locationsCount":55},"100550726","prospect-prior-2-chemo-prior-dental-intervention-before-chemo-to-reduce-chemotherapy-complications-100550726","NCT06450821","PROSpECT-PRIOR-2-CHEMO: PRIOR Dental Intervention Before Chemo to Reduce Chemotherapy Complications","PROSpECT-PRIOR-2-CHEMO: A Feasibility RCT of Novel Dental Intervention PRIOR[Proactive Intensive Oral Review & Treatment] in Patients Scheduled for Chemotherapy for Myeloma-ASCT & Hematological Cancers to Mitigate Chemotherapy Complications","Inclusion Criteria (mod-high\u002Frisk trial participants):\n\n* Adults (≥ 18years) with scheduled Chemotherapy. Specifically, patients who meet the following diagnosis and treatment window requirements:\n\n  * Myeloma- Autologous Stem Cell Transplantation (ASCT) before high-dose myeloablative CT.\n  * Haematological cancers suitable for Allografts Stem Cell Transplant (SCT) before CT\n* Moderate \u002F High Oral Health Risk Assessment - any one of the following:\n\n  * Clinical evidence of caries (2+ teeth)\n  * Clinical evidence on soft and hard tissue examination of infection, sinus, swelling or tenderness\n  * BPE code 3-4 in any remaining sextant\n  * BPE code 1-2 with \\>30% BOP\n* The patient is fully informed, has received PIS (patient information sheet) and considered during a 'cooling-off' period, is competent to consent, and is able to comply with minimum attendance requirements\n\nExclusion Criteria:\n\n* Have a history of head and neck radiotherapy\n* Have been treated with Denusomab, Bevacizumab, Sunitinib or Aflibercept within 9 months of the MDT date.\n* Insufficient teeth \\[defined as \\\u003C2\\]\n* Are incapable of providing informed written consent\n* Are unable to comply with minimum attendance requirements",{"count":155,"type":22},[25],"The aim of this feasibility trial is to determine if it is safe and feasible to treat oral health diseases in people with haematological cancers before they start their chemotherapy to reduce complications and disruption to planned chemotherapy dose or schedule.",[622,623,36,624,625],"Oncology","Periodontitis","Oral Mucositis","Febrile Neutropenia","2024-06-04",{"date":628,"type":48},"2024-06-10",{"date":630,"type":22},"2024-07",{"date":632,"type":22},"2026-10",{"name":634,"class":78},"University of Leeds",{"id":636,"slug":637,"hasResults":12,"nctId":638,"briefTitle":639,"officialTitle":639,"acronym":4,"eligibilityCriteria":640,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":641,"targetDuration":643,"studyType":237,"phases":4,"briefSummary":644,"conditions":645,"keywords":4,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":647,"lastUpdatePostDateStruct":648,"startDateStruct":650,"completionDateStruct":652,"leadSponsor":654,"locationsCount":55},"100295869","bergamo-lymphoid-cancer-registry-100295869","NCT03131531","Bergamo Lymphoid Cancer Registry","Inclusion Criteria:\n\n* Male or female patients 18 years or older\n* Written informed consent\n* Confirmed diagnosis of Hodgkin disease, non-Hodgkin lymphomas or myeloma\n\nExclusion Criteria:\n\n\\- Unconfirmed diagnosis of Hodgkin disease, non-Hodgkin lymphomas or myeloma",{"count":642,"type":22},6000,"20 Years","This registry has been established to gain a better understanding of the clinical and biological characteristics and outcome of patients with lymphoid cancer",[96,646,36],"Non Hodgkin Lymphoma","2024-03-05",{"date":649,"type":48},"2024-03-06",{"date":651,"type":48},"2017-03-23",{"date":653,"type":22},"2037-03-23",{"name":655,"class":78},"A.O. Ospedale Papa Giovanni XXIII"]